A $5 billion blockbuster emerges? JPMorgan maintains "Neutral" rating on Amgen (AMGN.US): A good drug does not equal a good entry point.

JPMorgan's latest research report says that Amgen (AMGN.US) over the weekend at the ESMO conference released Imdelltra first-line maintenance treatment data that was "impressive," and may support the drug's advance into earlier treatment lines, making it a potential $5 billion blockbuster. However, the firm still maintains a "Neutral" rating with a target price of $350, below the current share price of about $439. How strong is the data? Overall survival HR 0.42, progression-free survival more than tripled At the weekend's European Society for Medical Oncology (ESMO) annual meeting, Amgen presented results from the Phase 3 DeLLphi-305 trial. In extensive-stage small cell lung cancer, a patient population widely recognized as "refractory," patients receiving Imdelltra combined with Astrazeneca PLC Sponsored ADR Imfinzi achieved a median overall survival (mOS) of 21.1 months, versus only 12.7 months for the Imfinzi-alone group, with a hazard ratio (HR) for death as low as 0.42. Even more median progression-free survival (mPFS): 7.4 months for the combination group versus only 1.9 months for the monotherapy group, an improvement of more than threefold. JPMorgan analyst Chris Schott said outright that the magnitude of this benefit "supports Imdelltra playing an important role in earlier treatment lines." Amgen plans to submit the data to the U.S. FDA in the near term. Given the magnitude of efficacy, JPMorgan believes it would be "no surprise" if the data were incorporated into NCCN and other treatment guidelines before full approval is obtained. Three major engines: doubled population, 2.5x treatment duration, improved compliance JPMorgan estimates that Imdelltra's advance into first-line treatment will bring a triple amplification effect: First, expansion of the target population. There are about 23,000 first-line small cell lung cancer patients in the United States, significantly higher than the approximately 14,000 in second-line, and as patient survival lengthens, this population will continue to expand. Second, treatment duration is significantly lengthened. The median treatment duration in DeLLphi-305 is about 2.5 times that of second-line use, meaning a longer revenue cycle per patient. Third, improved accessibility and compliance. Previously the first two infusions required 22-24 hours of monitoring, now reduced to 6-8 hours, and first-line maintenance treatment reduced to 1-2 hours; combined with a lower incidence of adverse events, this will directly higher penetration. With the three combined, JPMorgan views Imdelltra as a potential $5 billion-plus blockbuster for Amgen and is bullish on its "upside" relative to consensus expectations. Behind the caution: Neutral rating, target price below current share price Despite the clear highlights in the pipeline, JPMorgan still maintains a "Neutral" rating on Amgen with a target price of $350about 20% below the October 23 closing price of $439.26. This cautious stance continues the firm's rating trajectory over the past two years: since January 2024 (target $290), October 2024 (target $300), and August 2026 (target $350), the rating has never been upgraded to "Overweight," and target price increases have clearly lagged the stock's actual gains. Small cell lung cancer has long been known as the "king of cancers," with rapid progression and poor prognosis, and the first-line standard regimen has long been dominated by PD-L1 inhibitors combined with chemotherapy. Imdelltra, as a bispecific T-cell engager, with this data in the first-line maintenance setting, brings an incremental option to this long "drug-deficient" area. For investors, the signal from this research report is clear: a good drug does not necessarily equal a good entry point. Whether the realization of Imdelltra's prospects can offset Amgen's concerns over the patent cliff, competitive pressure, and overall pipeline return rate will be key to determining the direction of its valuation.